Tang T, et al. - The value of the aspartate aminotransferase-to-platelet ratio index (APRI) for hepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolisation (TACE) were assessed in this study. The outcome suggests that the APRI is a promising marker to predict treatment response and outcome for HCC patients after TACE treatment.